Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Isolex 300 & 300i Magnetic Cell Selection System

Product: Isolex 300 & 300i Magnetic Cell Selection System
Nexell Therapeutics, Inc., Irvine, CA
PMA number:
BP970001 & BP970001 Supplement 01
Indication for Use:
Processing autologuous peripheral blood progenitor cell (PBPC) products to obtain a CD 34+ cell enriched population intended for hematopoietic reconstitution after myeloablative therapy in patients with CD 34-negative tumors.
Approval Date:

Letter (PDF), (Text)

Label (PDF)

Summary (PDF)

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 01/29/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.